Willingness to Pay for a Newborn Screening Test for Spinal Muscular Atrophy

Pediatric Neurology

Volumn 66, Issue , 2017, Pages 69-75

  Lin, Pei Jung ^a   Yeh, Wei Shi ^b   Neumann, Peter J ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b BIOGEN   (United States)

Author keywords

newborn screening; preferences; spinal muscular atrophy; willingness to pay

Indexed keywords

ADULT; ARTICLE; BLACK PERSON; DIAGNOSTIC ACCURACY; FEMALE; HEALTH CARE AVAILABILITY; HOUSEHOLD INCOME; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MIDDLE AGED; NEWBORN; NEWBORN SCREENING; PARENTAL ATTITUDE; PRIORITY JOURNAL; RACE DIFFERENCE; SPINAL MUSCULAR ATROPHY; WILLINGNESS TO PAY; ECONOMICS; GENETIC SCREENING; GENETICS; INCOME; INTERNET; PARENT; PSYCHOLOGY; QUESTIONNAIRE; UNITED STATES;

FEMALE; GENETIC TESTING; HUMANS; INCOME; INFANT, NEWBORN; INTERNET; MALE; MIDDLE AGED; MUSCULAR ATROPHY, SPINAL; NEONATAL SCREENING; PARENTS; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 85007439582     PISSN: 08878994     EISSN: 18735150     Source Type: Journal    
DOI: 10.1016/j.pediatrneurol.2016.09.008     Document Type: Article

References (32)

1. 1 Howell, R.R., We need expanded newborn screening. Pediatrics 117 (2006), 1800–1805.
2. 2 Swoboda, K.J., Seize the day: Newborn screening for SMA. Am J Med Genet A 152A (2010), 1605–1607.
3. 3 Neumann, P.J., Cohen, J.T., Hammitt, J.K., et al. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ 21 (2012), 238–251.
4. 4 Payne, K., Nicholls, S., McAllister, M., Macleod, R., Donnai, D., Davies, L.M., Outcome measurement in clinical genetics services: a systematic review of validated measures. Value Health 11 (2008), 497–508.
5. 5 Prior, T.W., Snyder, P.J., Rink, B.D., et al. Newborn and carrier screening for spinal muscular atrophy. Am J Med Genet A 152A (2010), 1608–1616.
6. 6 Asch, D.A., Patton, J.P., Hershey, J.C., Knowing for the sake of knowing: the value of prognostic information. Med Decis Making 10 (1990), 47–57.
7. 7 Lee, D.W., Neumann, P.J., Rizzo, J.A., Understanding the medical and nonmedical value of diagnostic testing. Value Health 13 (2010), 310–314.
8. 8 Dolgin, E., Call in the backup. Nat Med 18 (2012), 1602–1606.
9. 9 Wang, C.H., Finkel, R.S., Bertini, E.S., et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 22 (2007), 1027–1049.
10. 10 Phan, H.C., Taylor, J.L., Hannon, H., Howell, R., Newborn screening for spinal muscular atrophy: Anticipating an imminent need. Semin Perinatol 39 (2015), 217–229.
11. 11 Mercuri, E., Bertini, E., Iannaccone, S.T., Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol 11 (2012), 443–452.
12. 12 Taylor, J.L., Lee, F.K., Yazdanpanah, G.K., et al. Newborn blood spot screening test using multiplexed real-time PCR to simultaneously screen for spinal muscular atrophy and severe combined immunodeficiency. Clin Chem 61 (2015), 412–419.
13. 13 Markowitz, J.A., Singh, P., Darras, B.T., Spinal muscular atrophy: a clinical and research update. Pediatr Neurol 46 (2012), 1–12.
14. 14 Lin, P.J., Cangelosi, M.J., Lee, D.W., Neumann, P.J., Willingness to pay for diagnostic technologies: a review of the contingent valuation literature. Value Health 16 (2013), 797–805.
15. 15 Drummond, M.F., Sculpher, M.J., Torrance, G.W., O'Brien, B.J., Stoddart, G.L., Contingent Valuation Studies. Methods for the Economic Evaluation of Health Care Programs. 3rd ed., 2005, Oxford University Press, Oxford, UK, 219–220.
16. 16 Prosser, L.A., Hammitt, J.K., Keren, R., Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children: theoretical and methodological considerations. Pharmacoeconomics 25 (2007), 713–726.
17. 17 KnowledgePanel Design Summary. GfK Website. Available at: http://www.gfk.com/Documents/GfK-KnowledgePanel-Design-Summary.pdf. Published 2013. Accessed January 28, 2015.
18. 18 Lin, P.J., Concannon, T.W., Greenberg, D., et al. Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents. Expert Rev Pharmacoecon Outcomes Res 13 (2013), 513–522.
19. 19 Hammitt, J.K., Zhou, Y., The economic value of air-pollution-related health risks in China: a contingent valuation study. Environ Resour Econ 33 (2006), 399–423.
20. 20 Newborn screening: toward a uniform screening panel and system. Genet Med 8 Suppl 1 (2006), 1S–252S.
21. 21 Newborn screening: toward a uniform screening panel and system–executive summary. Pediatrics 117 (2006), S296–S307.
22. 22 Tarini, B.A., Goldenberg, A.J., Ethical issues with newborn screening in the genomics era. Annu Rev Genomics Hum Genet, 13, 2012, 381.
23. 23 Ross, L.F., Saal, H.M., David, K.L., Anderson, R.R., Technical report: ethical and policy issues in genetic testing and screening of children. Genet Med 15 (2013), 234–245.
24. 24 Search Results. Clinical Trials Registry and Results Database Website. Available at: http://clinicaltrials.gov/ct2/results?term=&recr=&rslt=&type=&cond=%22Spinal+Muscular+Atrophy%22&intr=drug&titles=&outc=&spons=&lead=&id=&state1=&cntry1=NA%3AUS&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=. Updated January 26, 2015. Accessed January 28, 2015.
25. 25 Fang, C., Otero, H.J., Greenberg, D., Neumann, P.J., Cost-utility analyses of diagnostic laboratory tests: a systematic review. Value Health 14 (2011), 1010–1018.
26. 26 Grosse, S.D., Wordsworth, S., Payne, K., Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med 10 (2008), 648–654.
27. 27 Qian, Y., McGraw, S., Henne, J., Jarecki, J., Hobby, K., Yeh, W.S., Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: a qualitative study. BMC Neurol, 15, 2015, 217.
28. 28 Rothwell, E., Anderson, R.A., Swoboda, K.J., Stark, L., Botkin, J.R., Public attitudes regarding a pilot study of newborn screening for spinal muscular atrophy. Am J Med Genet A 161A (2013), 679–686.
29. 29 Calonge, N., Green, N.S., Rinaldo, P., et al. Committee report: Method for evaluating conditions nominated for population-based screening of newborns and children. Genet Med 12 (2010), 153–159.
30. 30 Bailey, D.B. Jr., Gehtland, L., Newborn screening: evolving challenges in an era of rapid discovery. Jama 313 (2015), 1511–1512.
31. 31 Gatheridge, M.A., Kwon, J.M., Mendell, J.M., et al. Identifying Non-Duchenne Muscular Dystrophy-Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs: A Review. JAMA Neurol 73 (2016), 111–116.
32. 32 Mendell, J.R., Shilling, C., Leslie, N.D., et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71 (2012), 304–313.